A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Saved in:
| Title: | A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. |
|---|---|
| Authors: | Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medical Center, New York, USA. Electronic address: cns9006@med.cornell.edu., Saad F; Montreal Cancer Institute, Montreal University Hospital Center (CHUM), Montreal, QC, Canada., Graff JN; Knight Cancer Institute, Oregon Health and Science University and VA Portland Health Care System, Portland, USA., Peer A; Department of Oncology, Rambam Health Care Center, Haifa, Israel., Vaishampayan UN; Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, USA., Leung E; Division of Nuclear Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada., Rosenbaum E; Institute of Oncology, Rabin Medical Center-Davidoff Cancer Center, Petah Tikva, Israel., Gurney H; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia., Epstein RJ; Department of Medical Oncology, The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia., Davis ID; Department of Medicine, Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia., Wu B; Clinical Statistics Oncology, Bayer HealthCare Pharmaceutical Inc, Whippany, USA., Trandafir L; Global Clinical Development, Bayer Consumer Care AG, Basel, Switzerland., Wagner VJ; Global Clinical Development, Bayer Consumer Care AG, Basel, Switzerland., Hussain M; Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Feb; Vol. 31 (2), pp. 257-265. Date of Electronic Publication: 2019 Dec 23. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
